Literature DB >> 24113870

Cbl ubiquitination of p85 is essential for Epo-induced EpoR endocytosis.

Gamze B Bulut1, Rita Sulahian, Huiyu Yao, Lily Jun-shen Huang.   

Abstract

Erythropoietin (Epo) binding to the Epo receptor (EpoR) elicits downstream signaling that is essential for red blood cell production. One important negative regulatory mechanism to terminate Epo signaling is Epo-induced EpoR endocytosis and degradation. Defects in this mechanism play a key role in the overproduction of erythrocytes in primary familial and congenital polycythemia (PFCP). Here we have identified a novel mechanism mediating Epo-dependent EpoR internalization. Epo induces Cbl-dependent ubiquitination of the p85 regulatory subunit of PI3K, which binds to phosphotyrosines on EpoR. Ubiquitination allows p85 to interact with the endocytic protein epsin-1, thereby driving EpoR endocytosis. Knockdown of Cbl, expression of its dominant negative forms, or expression of an epsin-1 mutant devoid of ubiquitin-interacting motifs all compromise Epo-induced EpoR internalization. Mutated EpoRs mimicking those from PFCP patients cannot bind p85, co-localize with epsin-1, or internalize on Epo stimulation and exhibit Epo hypersensitivity. Similarly, knockdown of Cbl also causes Epo hypersensitivity in primary erythroid progenitors. Restoring p85 binding to PFCP receptors rescues Epo-induced epsin-1 co-localization and EpoR internalization and normalizes Epo hypersensitivity. Our results uncover a novel Cbl/p85/epsin-1 pathway in EpoR endocytosis and show that defects in this pathway contribute to excessive Epo signaling and erythroid hyperproliferation in PFCP.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24113870      PMCID: PMC3854114          DOI: 10.1182/blood-2013-05-506212

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt.

Authors:  Y Hakak; Y S Hsu; G S Martin
Journal:  Oncogene       Date:  2000-06-29       Impact factor: 9.867

Review 2.  Ubiquitin and ubiquitin-like proteins as multifunctional signals.

Authors:  Rebecca L Welchman; Colin Gordon; R John Mayer
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

Review 3.  Endocytic adaptors--social networking at the plasma membrane.

Authors:  Amanda Reider; Beverly Wendland
Journal:  J Cell Sci       Date:  2011-05-15       Impact factor: 5.285

4.  RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation.

Authors:  C B Thien; F Walker; W Y Langdon
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

5.  A PI3K activity-independent function of p85 regulatory subunit in control of mammalian cytokinesis.

Authors:  Zaira García; Virginia Silio; Miriam Marqués; Isabel Cortés; Amit Kumar; Carmen Hernandez; Ana I Checa; Antonio Serrano; Ana C Carrera
Journal:  EMBO J       Date:  2006-10-05       Impact factor: 11.598

6.  SH2 domain specificity determination using oriented phosphopeptide library.

Authors:  Z Songyang; L C Cantley
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

7.  Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins.

Authors:  D L Barber; J M Mason; T Fukazawa; K A Reedquist; B J Druker; H Band; A D D'Andrea
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

8.  Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3-kinase results in cell transformation.

Authors:  M Dean Chamberlain; Tim Chan; Jennifer C Oberg; Andrea D Hawrysh; Kristy M James; Anurag Saxena; Jim Xiang; Deborah H Anderson
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

9.  The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human hematopoietic cells.

Authors:  H Odai; K Sasaki; A Iwamatsu; Y Hanazono; T Tanaka; K Mitani; Y Yazaki; H Hirai
Journal:  J Biol Chem       Date:  1995-05-05       Impact factor: 5.157

10.  Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia.

Authors:  Rita Sulahian; Ondine Cleaver; Lily Jun-shen Huang
Journal:  Blood       Date:  2009-03-31       Impact factor: 22.113

View more
  12 in total

1.  Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.

Authors:  Matthew A Held; Emily Greenfest-Allen; Su Su; Christian J Stoeckert; Matthew P Stokes; Don M Wojchowski
Journal:  Cell Signal       Date:  2020-02-03       Impact factor: 4.315

2.  Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations.

Authors:  Stephan Wilmes; Maximillian Hafer; Joni Vuorio; Julie A Tucker; Hauke Winkelmann; Sara Löchte; Tess A Stanly; Katiuska D Pulgar Prieto; Chetan Poojari; Vivek Sharma; Christian P Richter; Rainer Kurre; Stevan R Hubbard; K Christopher Garcia; Ignacio Moraga; Ilpo Vattulainen; Ian S Hitchcock; Jacob Piehler
Journal:  Science       Date:  2020-02-07       Impact factor: 47.728

3.  Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia.

Authors:  Ilaria Iacobucci; Yongjin Li; Kathryn G Roberts; Stephanie M Dobson; Jaeseung C Kim; Debbie Payne-Turner; Richard C Harvey; Marcus Valentine; Kelly McCastlain; John Easton; Donald Yergeau; Laura J Janke; Ying Shao; I-Ming L Chen; Michael Rusch; Sasan Zandi; Steven M Kornblau; Marina Konopleva; Elias Jabbour; Elisabeth M Paietta; Jacob M Rowe; Ching-Hon Pui; Julie Gastier-Foster; Zhaohui Gu; Shalini Reshmi; Mignon L Loh; Janis Racevskis; Martin S Tallman; Peter H Wiernik; Mark R Litzow; Cheryl L Willman; John D McPherson; James R Downing; Jinghui Zhang; John E Dick; Stephen P Hunger; Charles G Mullighan
Journal:  Cancer Cell       Date:  2016-02-08       Impact factor: 31.743

Review 4.  Emerging EPO and EPO receptor regulators and signal transducers.

Authors:  David Kuhrt; Don M Wojchowski
Journal:  Blood       Date:  2015-04-17       Impact factor: 22.113

5.  Regulation of Smoothened ubiquitylation and cell surface expression through a Cul4-DDB1-Gβ E3 ubiquitin ligase complex.

Authors:  Shuang Li; Yong Suk Cho; Bing Wang; Shuangxi Li; Jin Jiang
Journal:  J Cell Sci       Date:  2018-08-01       Impact factor: 5.285

6.  Erythropoietin enhances Kupffer cell number and activity in the challenged liver.

Authors:  Dafna Gilboa; Yasmin Haim-Ohana; Naamit Deshet-Unger; Nathalie Ben-Califa; Sahar Hiram-Bab; Debby Reuveni; Ehud Zigmond; Max Gassmann; Yankel Gabet; Chen Varol; Drorit Neumann
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

7.  New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis.

Authors:  Florence Pasquier; Caroline Marty; Thomas Balligand; Frédérique Verdier; Sarah Grosjean; Vitalina Gryshkova; Hana Raslova; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker; Christine Bellanné-Chantelot; Isabelle Plo
Journal:  Haematologica       Date:  2017-12-21       Impact factor: 9.941

Review 8.  Cytokine Receptor Endocytosis: New Kinase Activity-Dependent and -Independent Roles of PI3K.

Authors:  Ping-Hung Chen; Huiyu Yao; Lily Jun-Shen Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-01       Impact factor: 5.555

9.  Pik3r1 Is Required for Glucocorticoid-Induced Perilipin 1 Phosphorylation in Lipid Droplet for Adipocyte Lipolysis.

Authors:  Taiyi Kuo; Tzu-Chieh Chen; Rebecca A Lee; Nguyen Huynh Thao Nguyen; Augusta E Broughton; Danyun Zhang; Jen-Chywan Wang
Journal:  Diabetes       Date:  2017-03-14       Impact factor: 9.461

10.  MARCH6 promotes hepatocellular carcinoma development through up-regulation of ATF2.

Authors:  Jie Sun; Zheng Dong; Zhengyao Chang; Hongfei Liu; Qiyu Jiang; Deyuan Zhang; Shanshan Lu; Xiaodong Jia; Dawei Wu; Aaron Ge; Pan Zhao; Jing Wang; Yinying Lu
Journal:  BMC Cancer       Date:  2021-07-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.